DexCom, Inc. (NASDAQ:DXCM) CEO Sells $2,287,209.24 in Stock

DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 32,498 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares of the company’s stock, valued at approximately $26,183,401.02. The trade was a 8.03 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

DexCom Stock Performance

DexCom stock opened at $70.69 on Friday. The company has a market capitalization of $27.62 billion, a PE ratio of 49.43, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a 50 day moving average price of $83.99 and a 200-day moving average price of $76.89. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Hedge Funds Weigh In On DexCom

Several institutional investors have recently bought and sold shares of DXCM. Versant Capital Management Inc purchased a new position in DexCom during the fourth quarter valued at approximately $25,000. Private Trust Co. NA grew its holdings in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares during the last quarter. Optiver Holding B.V. purchased a new position in DexCom in the fourth quarter worth $33,000. TD Private Client Wealth LLC grew its holdings in DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after purchasing an additional 167 shares during the last quarter. Finally, Larson Financial Group LLC grew its holdings in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after purchasing an additional 137 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on DXCM. Morgan Stanley increased their price target on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Canaccord Genuity Group raised their price objective on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Finally, Citigroup raised their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.